^
Association details:
| Biomarker: | CCDC6-RET fusion |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | agerafenib (RXDX-105) (BRAF inhibitor, RET inhibitor, CS-1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected
Excerpt:
Only one patient with right sided, MSS RET-positive mCRC received an anti-EGFR-based therapy and rapidly progressed. Conversely, an immunotherapy-naıve patient affected by a right sided, MSI-high and CCDC6-RET positive mCRC achieved a complete response to RXDX-105...
DOI:
10.1093/annonc/mdy090
Trial ID:
